Solving Kids' Cancer

The NCCA UK Jamie Inglis Appeal

Fundraising for Solving Kids’ Cancer UK
£142,349
raised of £250,000 target
by 2704 supporters
Donations cannot currently be made to this page
Event: Neuroblastoma Alliance - Jamie Inglis Appeal, from 31 December 2012 to 31 March 2013
We fund research and support families to access clinical trials for children.

Story

 

It is with immense sadness that we report the news that Jamie Inglis lost his battle against neuroblastoma on 15 January 2013.

 

He passed away peacefully in hospital with his parents by his side. Jamie’s appeal was raising funds to cover his treatment costs in Germany. After these costs have been met, Jamie’s mum and Dad have asked that any remaining money is allocated to help other children having neuroblastoma treatment now and to fund research into this frighteningly aggressive cancer.

 

You can still fundraise in memory of Jamie and we are aware that many of his supporters are planning to do so. We have set up a new page in memory of this wonderful little boy called ‘Jamie’s Lasting Legacy’. Please click here to see his new page.

 

This fundraising page will also remain open for the time being.

 

From Jamie’s family and the team at the Neuroblastoma Alliance UK, thank you for your support for Jamie’s appeal and for all the messages of support for Jamie and his family.

 

What is neuroblastoma?

Neuroblastoma is a very aggressive childhood cancer.   

 

·          2 children are diagnosed with neuroblastoma every week in the UK

 

·          1 of those babies and children will have high risk disease, where the cancer has spread to other parts of their body like the liver, bones and bone marrow, lungs, skin and brain

 

·          It causes 15% of childhood cancer deaths 

 

·          It is the commonest ‘solid’ cancer diagnosed in babies and children

 

·          The long term survival rate for babies and children with high risk neuroblastoma is less than 40%—half the average survival rate for other childhood cancers

 

Treatments

Children with high risk neuroblastoma can receive chemotherapy, surgery, radiation therapy, stem cell transplant and immunotherapy. Different clinical treatments are being trialled in Europe—including the UK—and the United States.

 

Not all children can join UK trials to get the potentially life-saving treatment they need. Some of the trials, especially for relapsed neuroblastoma, are only available abroad.

 

About the Neuroblastoma Alliance UK

We believe that UK children with neuroblastoma should have access to the best clinical treatment available to them locally or internationally. Taking into consideration the individual nature of the disease, the best treatments available may differ for each child.

 

If children cannot join a British trial, or need a clinical treatment that is only available outside the UK, they may have to travel abroad to give them the best chance of beating the disease.

 

Children’s treatment options should not be limited by where they live.

 

What we do

The Neuroblastoma Alliance UK helps children with neuroblastoma, a very aggressive childhood cancer, if they can't join UK trials or need a clinical treatment that is only available abroad.  

 

We need your help to fund children’s treatment costs, to support families and to pay for research into the disease.

 

Find out more

We welcome any questions you may have about our work. Please call us any time on telephone 020 8203 0100 and 020 8202 9065 or email us on info@nballiance.org.uk. You can also contact us through our website.

 

About the charity

Donations are paid into Solving Kids' Cancer’s general funds for our charitable activities. We help families affected by neuroblastoma through the provision of support and information; as well as investing in research and advocating for access to better treatment

Donation summary

Total raised
£142,348.30
+ £16,376.82 Gift Aid
Online donations
£93,440.87
Offline donations
£48,907.43

* Charities pay a small fee for our service. Find out how much it is and what we do for it.